Hemagen Diagnostics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HMGN research report →
Companywww.hemagen.com
Hemagen Diagnostics, Inc. , a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins.
- CEO
- William Hales
- IPO
- 1993
- Employees
- 15
- HQ
- Columbia, MD, US
Price Chart
Valuation
- Market Cap
- $3.10K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -18.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 39.92%
- Op Margin
- -10.83%
- Net Margin
- -22.45%
- ROE
- 29.06%
- ROIC
- -29.79%
Growth & Income
- Revenue
- $4.04M · -21.38%
- Net Income
- $-907,315 · -3.05%
- EPS
- $-0.06 · 2.50%
- Op Income
- $-437,914
- FCF YoY
- -14.26%
Performance & Tape
- 52W High
- $0.13
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.36
- Avg Volume
- 508
Get TickerSpark's AI analysis on HMGN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HMGN Coverage
We haven't published any research on HMGN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HMGN Report →